Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on October 16, 2017, for OrthoPediatrics Corp. The filing primarily documents the closing of the Company's Initial Public Offering (IPO) and related corporate governance changes.
Key Financial Metrics and Capital Structure
- IPO Details: The Company sold 4,600,000 shares of Common Stock at an offering price of $13.00 per share.
- Capitalization: The Amended and Restated Certificate of Incorporation increased the authorized Common Stock to 50,000,000 shares and authorized 5,000,000 shares of undesignated preferred stock.
- Financial Performance: The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period.
Material Changes and Corporate Actions
- Material Definitive Agreements: Entered into a Stockholders Agreement and a First Amendment to Registration Rights Agreement with Squadron Capital LLC.
- Executive Compensation: Granted restricted stock awards to three named executive officers under the 2017 Incentive Award Plan:
- Fred L. Hite (CFO): 10,500 shares
- David R. Bailey (EVP): 3,685 shares
- Gregory A. Odle (EVP): 11,725 shares
Awards vest in full on the six-month anniversary of the grant date, subject to continued service or specific termination conditions.
- Governance Changes:
- Established a classified board of directors with three classes serving staggered three-year terms.
- Restricted director removal to "for cause" only.
- Designated the Court of Chancery of the State of Delaware as the exclusive forum for specific legal actions.
Outlook, Risks, and Contingencies
The filing does not contain specific forward-looking guidance, risk factors, or management commentary regarding future financial performance beyond the standard disclosures incorporated by reference in the Registration Statement. The Company is identified as an emerging growth company.
Investor Verification Checklist
- Verify the total net proceeds from the IPO after deducting underwriting discounts and offering expenses (not explicitly stated in this text).
- Review the full text of the Stockholders Agreement (Exhibit 10.1) for specific rights granted to Squadron Capital LLC.
- Confirm the vesting schedule and forfeiture conditions for the restricted stock awards granted to executives.
- Examine the Amended and Restated Certificate of Incorporation (Exhibit 3.1) for details on the preferred stock series and anti-takeover provisions.